Streaming Titan Stumbles on Slower Signups, Slumps 8%

A global beverage giant beat revenue forecasts with a mix of price hikes and steady demand, a pharma heavyweight topped profit estimates, and a major streaming platform is sliding after missing user growth targets. Here’s what you need to know.

Crypto (Sponsored)

This Bitcoin Infrastructure Play Could Shock the Market on May 1st

A rare opportunity is unfolding in the Bitcoin infrastructure space—and few investors are paying attention.

One profitable company has already posted $144 million in 2024 revenue and $80.4 million in EBITDA. Yet despite real momentum and real numbers, it remains under the radar—still waiting for a senior exchange listing.

(By clicking the link above, you agree to receive emails from Huge Alerts. You can opt out at any time. - Privacy Policy)

That could be about to change.

They’ve filed a Form 40 with the SEC, setting up a potential market-moving event on May 1st. Once the broader market catches on, today's price levels could disappear.

Get all the details now—before the story goes mainstream.

[Click here to access the full briefing.]

(By clicking the link above, you agree to receive emails from Huge Alerts. You can opt out at any time. - Privacy Policy)

Futures 📈

What to Watch

Earnings:

Economic Reports:

Energy Sector (Sponsored)

This Nuclear Revival Could Spark the Next Big Move in Energy Stocks

Global energy markets are changing fast—and nuclear power is staging a powerful comeback.

With uranium prices rising and governments investing billions in next-generation reactors, a new wave of nuclear stocks is catching investor attention.

(By clicking the link above, you agree to receive emails from MarketBeat. You can opt out at any time. - Privacy Policy)

A newly released report breaks down 7 nuclear companies best positioned to ride this trend—some backed by steady defense contracts, others tied to the surging price of uranium.

Before these tickers hit the mainstream, see the full list—completely free.

[Click here to access the 7 stock picks now.]

(By clicking the link above, you agree to receive emails from MarketBeat. You can opt out at any time. - Privacy Policy)

Beverages

Strong Demand and Higher Prices Lift Coca-Cola’s Q1 Results

Coca-Cola (NYSE: KO) reported first-quarter results today that are better than Wall Street's expectations, helped by price hikes and resilient demand for its beverages, including sodas and its Fairlife milk brand.

Shares are up about 1% in premarket trading following the announcement.

The beverage giant’s average selling prices climbed 5% during the quarter, while unit case volumes rose by 2%, signaling that customers remained willing to pay more despite broader concerns about inflation and a softer consumer spending environment.

Don’t miss: These dark pool alerts may reveal stocks about to move—claim them now. (ad)

In particular, Coca-Cola credited strength in high-inflation regions such as Argentina and other Latin American markets for driving pricing gains.

While major peers like PepsiCo and Procter & Gamble have reported weaker consumer demand trends, Coca-Cola saw continued momentum in North America, especially within its sparkling drinks and dairy offerings.

For the quarter, Coca-Cola posted a revenue of $11.22 billion, nearly flat compared to $11.23 billion a year earlier.

Analysts had anticipated a decline of 0.84% to $11.14 billion, meaning Coca-Cola managed to beat consensus forecasts.

Despite ongoing challenges from inflation and tariff-related pressures globally, Coca-Cola’s pricing power and brand strength have enabled it to maintain sales levels.

Investors will now be watching to see how the company navigates the rest of the year amid a still-uncertain macroeconomic backdrop.

Pharmaceuticals

Pfizer Tops Profit Forecasts on Strong Vyndaqel Sales and Cost Cuts

Pfizer (NYSE: PFE) reported first-quarter earnings today that are better than Wall Street projections, aided by aggressive cost-cutting efforts and strong sales of its heart disease treatment, Vyndaqel.

Adjusted earnings touched 92 cents per share, significantly higher than the 66 cents per share analysts had anticipated, according to LSEG data.

The pharmaceutical giant’s total revenue for the quarter is $13.70 billion, slightly trailing the consensus estimate of $13.91 billion.

Urgent: This rare convergence of crypto catalysts may never happen again—act now or miss out. (ad)

Despite the revenue miss, shares of Pfizer are up about 1% in premarket trading, offering investors a positive start to the day after a challenging year that has seen the stock decline by over 13%.

Investors are keeping a close eye on the company's vaccine portfolio amid potential policy shifts under newly appointed U.S. health secretary Robert F. Kennedy Jr., known for his skepticism toward vaccines.

Any major changes could have significant implications for Pfizer’s vaccine-related earnings, particularly in a post-pandemic landscape.

Pfizer, along with other drugmakers, also faces the possibility of new tariffs on pharmaceutical imports, especially raw materials sourced from China — a key supplier for the industry. Rising costs from these duties could pressure margins if implemented.

As the company navigates these risks, Pfizer’s efforts to streamline operations and its continued momentum in specialized treatments like Vyndaqel are helping to stabilize performance in a turbulent healthcare market.

Magnificent Seven 2.0 (Sponsored)

7 Under-the-Radar Stocks With Game-Changing Potential

Everyone knows the Magnificent Seven—Apple, Amazon, Tesla, and the rest. But those stocks have already made their historic runs.

The real opportunity now? Spotting the next generation of market leaders before they go mainstream.

A brand-new report just revealed 7 under-the-radar companies with the potential to mirror the rise of the original Magnificent Seven.

They’re growing fast, expanding market share, and still flying below Wall Street’s radar—for now.

[Get the names and tickers before the next bull run begins.]

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.)

Streaming Music

Spotify Shares Slide After Weak Q2 User Forecast

Spotify (NYSE: SPOT) is seeing its shares fall more than 8% early Tuesday after issuing lower-than-expected guidance for second-quarter user growth and profitability.

The streaming giant now anticipates 689 million monthly active users (MAUs) for Q2, trailing the 694 million consensus.

For the first quarter, Spotify reported 678 million MAUs, a 10% increase from the previous year, but slightly below expectations.

You might like: A hidden options system has worked 97% of the time for 8 years—find out the exact phrase now. (ad)

Premium subscribers are up 12% year-over-year to 268 million, marking the second-highest Q1 net addition for the company.

Despite strong subscriber retention and engagement, CEO Daniel Ek acknowledged that near-term volatility may persist, while reaffirming confidence in Spotify's long-term growth trajectory.

Financially, Spotify posted Q1 gross margins of 31.6%, just above Wall Street's consensus but lower than its record 32.2% in the previous quarter.

The company’s second-quarter gross margin guidance of 31.5% slightly missed analysts’ estimates.

Analysts note that margin expansion may decelerate due to renegotiated contracts with major music labels.

Spotify shares had surged earlier this year, hitting all-time highs around $652 in February, driven by a company-wide restructuring, significant cost reductions, and expanded pricing tiers including audiobooks and bundled streaming plans.

However, concerns over macroeconomic uncertainty and slowing margin growth have recently weighed on sentiment.

Going forward, advertising revenue—which accounts for about 12% of total income—will be a key focus area amid broader market headwinds.

Tevogen Bio Holdings Inc. [TVGN] - Last Close: $0.94

Tevogen Bio is a clinical-stage biotech company developing therapies for cancer and infectious diseases.

Its shares are up 14% in premarket trading after the company reaffirmed its ambitious revenue forecast for its oncology pipeline. Management projects $1 billion in revenue in the launch year and a cumulative $10–14 billion over five years.

Leggett & Platt, Incorporated [LEG] - Last Close: $7.27

Leggett & Platt is a diversified manufacturer known for its engineered components and products used in bedding, furniture, flooring, and automotive markets.

Its shares are rising sharply in premarket after the company posted Q1 adjusted earnings that exceeded Wall Street expectations. Earnings came in at $0.24 per diluted share, beating the consensus estimate of $0.22. More importantly, Leggett reaffirmed its full-year 2025 guidance, projecting $1.00–$1.20 per share in adjusted earnings and $4.0–$4.3 billion in revenue.

Beyond, Inc. [BYON] - Last Close: $4.18

Beyond is a digital retail company operating familiar brands like Bed Bath & Beyond, Overstock, and Zulily.

Its shares are surging 16% in premarket trade today after the company reported a much narrower Q1 loss than expected. The adjusted loss came in at $0.42 per share, significantly better than analysts’ estimate of a $0.65 loss.

Uranium Supply Crunch (Sponsored)

On Behalf of Azincourt Energy Corp

The US Uranium Crisis = A Big Opportunity

Right now, the US has 94 nuclear reactors.

And 90% of the fuel they run on? It’s imported.

Tariffs are coming. Tensions are rising. And the government knows it needs more domestic-friendly supply.

That’s why the billionaires are piling in.

Why Peter Thiel just joined the board of a uranium enrichment startup. Why Canada’s uranium is now more strategic than ever.

And why one tiny explorer in Saskatchewan’s Athabasca Basin could be positioned perfectly. The company has two active projects.

It’s drilling in the richest uranium district on Earth.

And as the US tries to secure its nuclear future, Canadian explorers like this one may be the first call utilities make.

Discover the full story behind this quietly rising stock.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club